about
Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapyNew insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposisEvidence for classification of c.1852_1853AA>GC in MLH1 as a neutral variant for Lynch syndromeIGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer.TGFBR1 intralocus epistatic interaction as a risk factor for colorectal cancer.EPCAM germ line deletions as causes of Lynch syndrome in Spanish patientsMethylation of tumor suppressor genes is related with copy number aberrations in breast cancerImmunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicinePrevalence of Lynch syndrome among patients with newly diagnosed endometrial cancers.Increased Risk of Colorectal Cancer in Patients With Multiple Serrated Polyps and Their First-Degree Relatives.Prevalence of MLH1 constitutional epimutations as a cause of Lynch syndrome in unselected versus selected consecutive series of patients with colorectal cancer.Endoscopic surveillance in patients with multiple (10-100) colorectal polyps.KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia.MicroRNA signatures in hereditary breast cancer.Prevalence and characteristics of MUTYH-associated polyposis in patients with multiple adenomatous and serrated polyps.TFAP2E Methylation and Expression Status Does Not Predict Response to 5-FU-based Chemotherapy in Colorectal Cancer.Clinical subtypes and molecular characteristics of serrated polyposis syndrome.Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancerClinically important molecular features of Peruvian colorectal tumours: high prevalence of DNA mismatch repair deficiency and low incidence of KRAS mutationsColorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapyReplyRelationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancerTrends of Adverse Events Following Immunization (AEFI) Reports of Human Papillomavirus Vaccine in the Valencian Community-Spain (2008-2018)
P50
Q26751035-19F9DFF2-B1C2-476C-8064-A4F591239A32Q28307340-020AA83D-54D6-43FD-9AD0-BE61BC010E60Q33797266-4ED83DB0-6182-4CDB-8194-668A3DD6F1BDQ34050656-34BA1491-DE08-49F1-9324-B714E86AB6B1Q34146418-FB0A5F21-EB3C-4013-BAB6-9641DDAECC19Q34239731-30D5C1D9-4919-4665-B30B-CF274E51DC5EQ34991280-90A84D81-786F-444C-B0DD-3A7AD1B25FB9Q35993199-54B00BFB-1C80-4DEA-A306-FF90512B41F9Q37288374-27B33DC3-66F7-48EF-BB03-226787FAD80FQ38841697-1DDD7649-5ABB-44AF-84BC-6B6E1CC6405DQ41019611-C1414498-8AB4-4ACD-BFD5-864A1247E58AQ41593799-9857FF87-17DE-4BDF-BAD6-9D7B92FFE770Q41853489-BF128870-6F5C-405B-820D-7A1BCB4E102AQ44685853-19E37563-D763-4092-9D7E-1DE3D6E5FBF1Q51756228-FB8EA6AE-51F4-4665-88FA-1A75E6479B38Q52657410-3C7B85BD-9A21-4CC8-B61F-6EA6E596D936Q54273482-62EB8D6D-A510-4F3C-8125-F279E97AD23EQ57083802-7E0FAD91-862A-45BC-8818-5DDE2A478BC0Q58068437-EB5F813E-C458-455E-95CE-C04AF3CFDA79Q58762177-D3104ADA-E29A-4B46-85C7-CAD7B5B3E7A9Q62029998-E8F97578-840E-4443-9E88-C26BA71E4897Q62030000-F0F49906-C720-4B82-A9DF-99C75F2DB521Q90048065-D16B8809-AE6B-47E0-A6B2-AE5A5DCE34B9
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Cecilia Egoavil
@ast
Cecilia Egoavil
@en
Cecilia Egoavil
@es
Cecilia Egoavil
@nl
Cecilia Egoavil
@sl
type
label
Cecilia Egoavil
@ast
Cecilia Egoavil
@en
Cecilia Egoavil
@es
Cecilia Egoavil
@nl
Cecilia Egoavil
@sl
altLabel
Cecilia M. Egoavil
@en
prefLabel
Cecilia Egoavil
@ast
Cecilia Egoavil
@en
Cecilia Egoavil
@es
Cecilia Egoavil
@nl
Cecilia Egoavil
@sl
P106
P21
P31
P496
0000-0003-0166-4901